Depot-bromocriptine treatment for prolactinomas and acromegaly.
Fifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot-bromocriptine. None of the patients had any short...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
1986
|
| _version_ | 1797055358933401600 |
|---|---|
| author | Grossman, A Ross, R Wass, J Besser, G |
| author_facet | Grossman, A Ross, R Wass, J Besser, G |
| author_sort | Grossman, A |
| collection | OXFORD |
| description | Fifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot-bromocriptine. None of the patients had any short-term or long-term discomfort from the injection. In the 11 patients with prolactinomas, serum prolactin fell to minimum levels 12-72 h post-injection; nine patients were highly responsive to depot-bromocriptine, with a mean serum prolactin of 12.9% of basal levels 24 h post-injection, rising to 19% at 28 days. Two patients with prolactinomas were resistant to both depot-bromocriptine, and large doses of oral dopamine agonists. Initiating side-effects (nausea, vomiting, symptomatic postural hypotension) were seen in five patients in the first 24 h post-injection, but were minimal or absent thereafter. Five of six patients previously intolerant of oral dopamine agonists were able to be transferred successfully to bromocriptine 5 mg daily at 4 weeks. Of the four patients with acromegaly, raised prolactin levels were successfully lowered to normal for 4 weeks after injection; serum GH was also partially lowered, but returned to baseline levels at 2-4 weeks. In one patient serum GH was resistant to suppression by both depot bromocriptine and high doses of oral bromocriptine. One patient with a large tumour and visual field defects showed a rapid and maintained improvement in visual fields and acuity after depot-bromocriptine, and was successfully transferred to high-dose oral bromocriptine at 4 weeks.(ABSTRACT TRUNCATED AT 250 WORDS) |
| first_indexed | 2024-03-06T19:09:35Z |
| format | Journal article |
| id | oxford-uuid:16515e36-ca30-4501-8d24-8315a6bb6e37 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:09:35Z |
| publishDate | 1986 |
| record_format | dspace |
| spelling | oxford-uuid:16515e36-ca30-4501-8d24-8315a6bb6e372022-03-26T10:30:36ZDepot-bromocriptine treatment for prolactinomas and acromegaly.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:16515e36-ca30-4501-8d24-8315a6bb6e37EnglishSymplectic Elements at Oxford1986Grossman, ARoss, RWass, JBesser, GFifteen patients with hyperprolactinaemia and pituitary macroadenomas (5 patients), microadenomas (6 patients), or acromegaly (4 patients) were given a single intramuscular injection of 50 mg bromocriptine bound to polylactic acid microspheres, depot-bromocriptine. None of the patients had any short-term or long-term discomfort from the injection. In the 11 patients with prolactinomas, serum prolactin fell to minimum levels 12-72 h post-injection; nine patients were highly responsive to depot-bromocriptine, with a mean serum prolactin of 12.9% of basal levels 24 h post-injection, rising to 19% at 28 days. Two patients with prolactinomas were resistant to both depot-bromocriptine, and large doses of oral dopamine agonists. Initiating side-effects (nausea, vomiting, symptomatic postural hypotension) were seen in five patients in the first 24 h post-injection, but were minimal or absent thereafter. Five of six patients previously intolerant of oral dopamine agonists were able to be transferred successfully to bromocriptine 5 mg daily at 4 weeks. Of the four patients with acromegaly, raised prolactin levels were successfully lowered to normal for 4 weeks after injection; serum GH was also partially lowered, but returned to baseline levels at 2-4 weeks. In one patient serum GH was resistant to suppression by both depot bromocriptine and high doses of oral bromocriptine. One patient with a large tumour and visual field defects showed a rapid and maintained improvement in visual fields and acuity after depot-bromocriptine, and was successfully transferred to high-dose oral bromocriptine at 4 weeks.(ABSTRACT TRUNCATED AT 250 WORDS) |
| spellingShingle | Grossman, A Ross, R Wass, J Besser, G Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title | Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title_full | Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title_fullStr | Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title_full_unstemmed | Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title_short | Depot-bromocriptine treatment for prolactinomas and acromegaly. |
| title_sort | depot bromocriptine treatment for prolactinomas and acromegaly |
| work_keys_str_mv | AT grossmana depotbromocriptinetreatmentforprolactinomasandacromegaly AT rossr depotbromocriptinetreatmentforprolactinomasandacromegaly AT wassj depotbromocriptinetreatmentforprolactinomasandacromegaly AT besserg depotbromocriptinetreatmentforprolactinomasandacromegaly |